William Blair analyst Brandon Vazquez has reiterated their bullish stance on EW stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Vazquez’s rating is based on several key developments surrounding Edwards Lifesciences. The initiation of a national coverage analysis by CMS for TAVR procedures is a significant step forward, as it aligns with expectations to broaden coverage to asymptomatic patients. This move is anticipated to reduce barriers for medical centers to offer TAVR and for patients to access this therapy, potentially unlocking a substantial patient population previously considered asymptomatic.
Furthermore, the expectation of an updated national coverage determination by mid-2026, with finalization by September 2026, supports a positive outlook for the company. Although the coverage will not be effective until the end of 2026, the developments are expected to create a positive perception around TAVR, benefiting Edwards Lifesciences in the coming quarters. With the stock trading at a multiple of 29.8 times the expected 2026 earnings per share, Vazquez maintains an Outperform rating, reflecting confidence in the company’s growth trajectory.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $95.00 price target.
Based on the recent corporate insider activity of 105 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year.